GO
Loading...

Pharmaceuticals

More

  • Painkiller Vioxx contributed to an Idaho postal worker's heart attack, a jury in Atlantic City ruled Monday, reversing the verdict in the man's first trial and hitting drugmaker Merck with a total of $47.5 million in damages.

  • Drugmaker Schering-Plough is buying Organon Biosciences for about $14.5 billion. Organon is part of the Dutch paint and chemical company Akzo Nobel whose shares are at a new high today on the news. Schering Chairman and CEO Fred Hassan has been saying for quite some time that he's "very much in the deal flow" on company conference calls and in interviews with CNBC, so the fact that he's making a big acquisition doesn't come as a huge shock.

  • Smith & Nephew to Buy Plus Orthopedics Monday, 12 Mar 2007 | 12:14 PM ET

    Smith & Nephew, a British maker of artificial hips, said Monday it agreed to buy Plus Orthopedics Holding, a private Swiss orthopedic company, for about 1.09 billion Swiss francs ($889 million; 617 million euros) in cash to boost its share of the orthopedic reconstruction market.

  • European Stocks to Watch Monday, 12 Mar 2007 | 11:53 AM ET

    Here some of Monday's big movers on European stock markets: Akzo Nobel, Alliance Boots, ICI,Swisscom and DSG International.

  • Schering-Plough Buys Akzo's Organon for $14.5 Billion Monday, 12 Mar 2007 | 10:59 AM ET

    Akzo Nobel said on Monday it was selling its drugs unit Organon BioSciences to Schering-Plough for 11 billion euros ($14.5 billion), dropping plans to float it in a public share offer.

  • Reasons to be Cheerful Monday, 12 Mar 2007 | 7:39 AM ET

    The CEO of Akzo Nobel may be feeling like a lottery winner this morning after making a deal with Schering-Plough.

  • Three Amgen Drugs to Carry New FDA Warning Friday, 9 Mar 2007 | 3:30 PM ET

    The U.S. Food and Drug Administration on Friday issued a public health advisory for three widely-used drugs manufactured by Amgen for the treatment of anemia.

  • Americans may not be getting access to generic drugs, even if they are available, CNBC's David Faber reports on tonight's edition of "Business Nation."

  • Hollis-Eden Pharmaceuticals said the U.S. government has canceled its request for proposal for a contract for its drug to treat acute radiation syndrome, sending its shares spiraling.

  • Shares of Insmed plunged after the tiny biotech company said it will restructure operations due to recently settled litigation with rival Tercica, which will keep Insmed's treatment for short stature in children off the U.S. market.

  • CV Therapeutics said its angina drug was not effective in a study of acute and long-term treatment of patients with a type of heart disease known as acute coronary syndrome.

  • Pfizer said the FDA approved Lipitor for new uses including treating nonfatal heart attacks, fatal and nonfatal strokes, certain types of types of heart surgery, hospitalization for heart failure, and chest pain in patients with heart disease.

  • Straight Talk From The Trading Floor Tuesday, 6 Mar 2007 | 8:36 PM ET

    The Fast Money Five give their picks for the hottest trades. Tonight, the burning rubber rally, the call ahead of Costco earnings and more...

  • CV Therapeutics said on Tuesday its angina drug Ranexa was not effective in a study of acute and long-term treatment of patients with a type of heart disease known as acute coronary syndrome.

  • Vioxx Verdict Upheld; Merck Boosts CEO's Salary Tuesday, 6 Mar 2007 | 2:33 AM ET

    A judge in the New Jersey Vioxx personal injury trial on Monday rejected a motion that would give one of the plaintiffs in the trial another opportunity to collect damages based on negligence from drug maker Merck.

  • Answers To Your Questions About The Sell-Off Monday, 5 Mar 2007 | 9:15 PM ET

    Brian from Missouri asked wither the slide we’re seeing today in the energy markets is going to help stocks. Also, what’s with this sell-off in the Euro and do you think it will continue? Eric Bolling answered....

  • Don't Believe the Hype Monday, 5 Mar 2007 | 6:14 PM ET

    It's time to step back from the madness and understand a basic tenet of the markets: Just because something negative happens somewhere, it doesn't mean the sky is falling. In fact, it could be good news for you. Here's why...

  • Is Amgen On Sale or For Sale? Monday, 5 Mar 2007 | 2:22 PM ET

    While no one was looking shares of Amgen, the world's biggest biotech company (by sales, not market cap--Genentech is #1 there) have fallen from nearly $76 on January 22nd to the low-60s. What happened? In a nutshell, the company has been buffeted by safety, reimbursement and competitive concerns about its biggest drug franchise known as the acronym EPO.

  • Glaxo Pipeline Dented as Mid-Stage Drugs Dropped Monday, 5 Mar 2007 | 8:58 AM ET

    GlaxoSmithKline's claim to have one of the best new drug pipelines in the industry has suffered a setback with the loss of a number of experimental medicines in mid-stage clinical testing.

  • Gen-Probe has won U.S. approval to sell its Procleix blood test to detect the West Nile virus, a Food and Drug Administration spokeswoman said Friday.